Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reps. Brady, McDermott Trade For Ways And Means Health Panel Posts

This article was originally published in The Pink Sheet Daily

Executive Summary

The top posts of the House Ways and Means Committee’s Health Subcommittee will be taken over by newcomers to the panel, with Kevin Brady, R-Texas, as chairman and Jim McDermott, D-Wash., as ranking member.

You may also be interested in...



Key House Medicare Subcommittee Will Have New Leaders; Rep. Stark Loses Election Bid

Rep. Pete Stark, D-Calif., often a critic of the pharmaceutical industry, lost his re-election bid, leaving the top Democratic spot open on the Ways and Means Committee’s Health Subcommittee. Subcommittee Chairman Wally Herger already planned to retire. All members of the Senate HELP and Finance Committees up for re-election won their races.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Deal Watch: Sanofi, Boehringer Swap Side Businesses

Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.

Topics

UsernamePublicRestriction

Register

PS074775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel